DRDAX Performance — Dearborn Partners Rising Dividend Fund, Class A
Data updated: 2026-10-08
DRDAX returned +4.08% year to date and −0.19% over one year to Aug 2026. Annualised returns are +8.08% over 3 years and +5.39% over 5 years. The fund trailed its US Large Value category average: $100 invested three years ago grew to $126, against $160 for the category, and to $100 over one year, against $118. Volatility over the past three years was 10.80% a year. In the 12 months to May 2026 the fund lost a net $66.7M, and assets reached $505.51M.
DRDAX Growth of $100
What $100 invested in Dearborn Partners Rising Dividend Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Value category average over the same months.
| Period | DRDAX | Category average |
|---|---|---|
| 1 year (Sep 2025 – Aug 2026) | $100 | $118 |
| 3 years (Sep 2023 – Aug 2026) | $126 | $160 |
| 5 years (Sep 2021 – Aug 2026) | $130 | $164 |
| Since data start (Mar 2020 – Aug 2026) | $175 | $234 |
DRDAX Trailing Returns
Total returns to Aug 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +4.08% |
| 1 year | −0.19% |
| 3 years (annualised) | +8.08% |
| 5 years (annualised) | +5.39% |
DRDAX Annual Returns
Calendar-year total returns of Dearborn Partners Rising Dividend Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Aug) | +4.08% |
| 2025 | +2.13% |
| 2024 | +12.81% |
| 2023 | +13.47% |
| 2022 | −11.78% |
| 2021 | +24.20% |
| 2020 (Mar–Dec) | +17.66% |
DRDAX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.0% | +2.7% | −5.2% | +2.6% | −1.1% | −1.9% | +4.2% | +2.1% | — | — | — | — |
| 2025 | +3.3% | +2.1% | −1.9% | −1.8% | +2.0% | +0.7% | −0.1% | +2.2% | −0.6% | −4.0% | +1.5% | −0.9% |
| 2024 | +0.2% | +2.9% | +1.9% | −4.1% | +2.8% | +1.4% | +4.3% | +2.9% | +2.0% | −1.4% | +5.5% | −5.8% |
| 2023 | +3.6% | −3.4% | +3.1% | +1.8% | −3.5% | +6.5% | +2.6% | −2.6% | −4.0% | −2.5% | +7.6% | +4.6% |
| 2022 | −6.7% | −4.0% | +4.4% | −5.0% | +0.7% | −5.7% | +8.1% | −3.1% | −8.7% | +8.3% | +6.6% | −5.4% |
| 2021 | −1.6% | 0.0% | +5.9% | +4.8% | −0.5% | +0.9% | +3.0% | +1.5% | −4.6% | +6.3% | +0.8% | +6.0% |
| 2020 | — | — | −11.6% | +10.0% | +5.2% | 0.0% | +5.9% | +3.5% | −2.1% | −2.1% | +7.0% | +2.4% |
DRDAX Risk
Risk measures from monthly returns over Sep 2023 – Aug 2026.
- 3-year volatility (annualised): 10.80%
- 3-year Sharpe ratio: 0.33 (vs 4.5% risk-free rate)
- Best month: +7.61% (Nov 2023)
- Worst month: −5.77% (Dec 2024)
DRDAX Fund Flows
Monthly money in and out of Dearborn Partners Rising Dividend Fund, from SEC Form N-PORT.
- 12-month net flow: −$66.7M
- 12-month gross sales (incl. reinvestments): $71.4M
- Sales ÷ redemptions: 0.52×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $4.2M | $13.3M | −$9.1M |
| Apr 2026 | $3.2M | $8.4M | −$5.2M |
| Mar 2026 | $4.8M | $12.9M | −$8.1M |
| Feb 2026 | $3.8M | $11.2M | −$7.4M |
| Jan 2026 | $3.3M | $22.2M | −$18.9M |
| Dec 2025 | $20.3M | $18.0M | $2.3M |
| Nov 2025 | $3.0M | $13.9M | −$10.9M |
| Oct 2025 | $5.4M | $13.1M | −$7.7M |
| Sep 2025 | $6.2M | $7.7M | −$1.5M |
| Aug 2025 | $4.1M | $6.9M | −$2.8M |
| Jul 2025 | $8.1M | $6.4M | $1.7M |
| Jun 2025 | $5.0M | $4.1M | $936K |
DRDAX Assets Under Management
Net assets of Dearborn Partners Rising Dividend Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-08-31 | $505.51M |
| 2026-05-31 | $519.86M |
| 2026-02-28 | $564.72M |
| 2025-11-30 | $589.92M |
| 2025-08-31 | $631.30M |
| 2025-05-31 | $615.04M |
| 2025-02-28 | $626.89M |
| 2024-11-30 | $642.93M |
| 2024-08-31 | $605.22M |
| 2024-05-31 | $555.40M |
| 2024-02-29 | $538.74M |
| 2023-11-30 | $498.41M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.